4875 MediciNova
- 220
- 00.00%
MediciNova News
MediciNova Receives Notice Of Allowance For New Patent Covering MN-166 (Ibudilast) For Chlorine-induced Acute Respiratory Distress Syndrome, Once Issued, This Patent Is Expected To Expire No Earlier Than January 2042
MediciNova Receives Notice Of Allowance For New Patent Covering MN-166 (Ibudilast) For Chlorine-induced Acute Respiratory Distress Syndrome, Once Issued, This Patent Is Expected To Expire No Earlier T
MediciNova (MNOV.US): The 2024 Q1 financial report achieved revenue of $0, with a previous value of $0; earnings per share of -$0.06, previous value of -$0.06, and expected value of -$0.05.
MediciNova (MNOV.US): The 2024 Q1 financial report achieved revenue of $0, with a previous value of $0; earnings per share of -$0.06, previous value of -$0.06, and expected value of -$0.05.
MediciNova: Consolidated Financial Results for the 1st Quarter of the Fiscal Year Ending 2024/12 [US GAAP] (Consolidated)
MediciNova: Supplementary explanation of financial results for the 1st quarter of the fiscal year ending 2024/12
MediciNova | 10-Q: Quarterly report
Kasai Kou, etc. [Mysterious brands seen from changes in turnover]
Stock closing price turnover compared to the previous day*＜7256＞Kasai Takumi 263 24 7407700*＜4875＞Medicinova 213 7 717600*＜3645＞Medical N 373 8 219600*＜6062＞Charm Care 1704 199 812500*＜6099＞Elan 1003 84 883800*＜4678＞Hidehide 309 10
MediciNova Anti-inflammatory Drug Gets Issue Notification for New Patent
12 Health Care Stocks Moving In Friday's After-Market Session
GainersLongeveron (NASDAQ:LGVN) stock rose 48.6% to $3.27 during Friday's after-market session. The company's market cap stands at $8.2 million. Adial Pharmaceuticals (NASDAQ:ADIL) shares increased by
Reported Earlier, Medicinova Announces Abstract Regarding Results Of A Clinical Trial Of MN-166 In Glioblastoma Accepted For Presentation At The 2024 ASCO
Abstract Number: 2106Title: Phase 1b/2a study evaluating the combination of MN-166 (ibudilast) and temozolomide in patients with newly diagnosed and recurrent glioblastoma (GBM)Session Title: Rapid O
MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (Ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)
Phase 1b/2a study evaluating the combination of MN-166 (ibudilast) and temozolomide in patients with newly diagnosed and recurrent glioblastoma (GBM).
MediciNova Vice President Geoffrey O'Brien Announces Retirement
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersLixte Biotechnology (NASDAQ:LIXT) shares moved upwards by 67.2% to $3.77 during Wednesday's pre-market session. The market value of their outstanding shares is at $8.4 million. Nutriband (NASDA
Reported Earlier, MediciNova Receives Notice Of Allowance From Japan Patent Office For MN-166 In Macular Injury Treatment
Once issued, this patent is expected to expire no earlier than October 2039. The allowed claims cover the use of MN-166 (ibudilast) for treating macular injury associated with progressive multiple sc
MediciNova Gets Patent in Japan for Multiple Sclerosis-Related Treatment
By Ben Glickman MediciNova said it had received a Japanese patent allowance for its treatment for macular injury linked to multiple sclerosis. The La Jolla, Calif.-based biopharmaceutical company sa
MediciNova Receives a Notice of Allowance For a New Patent Covering MN-166 (Ibudilast) for the Treatment of Macular Injury in Japan
MediciNova, Inc (NASDAQ:MNOV) today announced it has received a Notice of Allowance from the Japan Patent Office for a pending patent application which covers MN-166 (ibudilast) for the treatment of macular injury associated with progressive multiple sclerosis.
Reported Earlier, MediciNova Announces Two Abstracts Regarding MN-001 And MN-002 Accepted For Presentation At The 92nd EAS 2024 Congress
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that two abstrac
Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth
MediciNova Reports Positive Results for Lung Injury Treatment
MediciNova Announces New Data and Results of MN-166 (Ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented At The Annual Meeting of the Society of Toxicology
MediciNova Announces New Data and Results of MN-166 (Ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented At The Annual Meeting of the Society of Toxicology
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
GainersJanux Therapeutics (NASDAQ:JANX) stock rose 120.5% to $33.3 during Tuesday's pre-market session. The market value of their outstanding shares is at $1.5 billion. Viking Therapeutics (NASDAQ:VKT
Analysis
Price Target
No Data
